Biomarin Pharmaceutical (BMRN) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

BMRN Biomarin Pharmaceutical

Watchlist

71.020
-0.140-0.20%

Close Mar 3 16:00 ET

70.710
-0.310-0.44%

Pre 04:27 ET

13.55BMarket Cap32.14P/E (TTM)

Pre-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Results: BioMarin Pharmaceutical Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Yahoo FinanceFeb 26 06:01 ET
Insider Sale: GVP of $BMRN Sells 1,344 Shares
Quiver QuantitativeFeb 25 20:30 ET
BioMarin to Present at the TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4 at 6:50 AM PT / 9:50 AM ET in Boston, MA
BioMarin PharmaceuticalFeb 25 00:00 ET
Stifel Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Maintains Target Price $91
Moomoo NewsFeb 24 21:31 ET · Ratings
Express News | Biomarin Announces Appointment of Timothy P. Walbert to Board of Directors
ReutersFeb 24 16:05 ET
Press Release: BioMarin Announces Appointment of Timothy P. Walbert to Board of Directors
Dow JonesFeb 24 16:05 ET

Comments

Moomoo AI

Mar 25, 2024 07:52

Recent insider selling at BioMarin Pharmaceutical raises caution despite high insider ownership. The history of share sales is concerning, though the company's earnings growth is positive.

Insiders At BioMarin Pharmaceutical Sold US$6.7m In Stock, Alluding To Potential Weakness

Moomoo AI

Mar 7, 2024 07:41

BioMarin's CEO, Alexander Hardy, expressed confidence in Hubbard's leadership and expertise in lifecycle management and delivering growth across multiple therapeutic areas. He anticipates that her deep experience in the biopharmaceutical industry will add to the talent within the organization.

Press Release: BioMarin Announces Appointment of Cristin Hubbard as Chief Commercial Officer

Moomoo AI

Feb 8, 2024 08:52

BioMarin Pharmaceutical Inc.'s low P/S ratio may be due to its sluggish growth forecast. The market's expectation of continued poor revenue growth could be suppressing the P/S. Shareholders' pessimism on the company's revenue prospects seems to be the main contributor to the depressed P/S.

BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Share Price Is Matching Sentiment Around Its Revenues

Moomoo AI

Jan 18, 2024 06:34

BioMarin Pharmaceutical's decent earnings growth and high rate of reinvestment are positive, despite low ROE. However, earnings growth could have been higher with improved ROE. Forecasts reveal expected earnings acceleration.

BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

Moomoo AI

Dec 21, 2023 10:14

Analysts see M&A as integral to BioMarin's value creation. Clarity on the market potential of Roctavian could stimulate transactional activities. A gene therapy division spin-off followed by a business sale is anticipated.